Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2008

View Archived Issues

Positive results emerge from phase III ALO-01 study in patients with osteoarthritis pain

rhEPO shows clinical benefits for the treatment of amyotrophic lateral sclerosis

Cenomed reports on new schizophrenia and posttraumatic stress disorder candidates

Mutation-specific effects seen with pyrimethamine in familial ALS patients

Novel means of avoiding opioid-related adverse events reported in recent Progenics patent

Recent GenkyoTex patent imparts novel therapeutics for cardiovascular disorders

New antiinflammatory agents reported in recent Biolipox patents

Alizyme presents update on clinical development activities between July and November 2008

FDA reschedules Advisory Committee meeting with Novo for liraglutide until April 2009

Memory completes enrollment in phase II trial of MEM-3454 in CI associated with schizophrenia

CytRx updates progress of third quarter 2008

Chelsea Therapeutics completes enrollment in phase II trial of droxidopa in IDH

GenVec reports interim results from phase III PACT trial of TNFerade

Phase III studies show vandetanib offers benefit to patients with lung cancer

BioDelivery Sciences to resubmit REMS for Onsolis to FDA in December 2008

Karo Bio and Wyeth extend drug discovery collaboration with LXR in inflammatory diseases

BI-201335 well tolerated, active in treatment-naive and -experienced HCV patients

Hyperphosphatemia controlled with fermagate in hemodialysis patients

Elixir's reports results from phase III trial of metformin-mitiglinide therapy

Telavancin receives favorable recommendation from FDA

Cougar Biotechnology commences phase I/II CB-7630 trial in breast cancer

Ortho Biotech submits NDA for trabectedin for relapsed ovarian cancer

Debiopharm and Aurigene sign licensing agreement for Debio-0617

Grazax approved in Europe for children with hay fever

Basilea's Zevtera receives positive opinion from the CHMP

GlaxoSmithKline receives FDA accelerated approval for Promacta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...